D.A. Davidson & CO. decreased its holdings in shares of Stryker Co. (NYSE:SYK) by 0.4% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 55,552 shares of the medical technology company’s stock after selling 227 shares during the period. D.A. Davidson & CO.’s holdings in Stryker were worth $12,016,000 as of its most recent SEC filing.
Other large investors have also bought and sold shares of the company. Founders Capital Management LLC boosted its stake in Stryker by 3.9% during the second quarter. Founders Capital Management LLC now owns 10,887 shares of the medical technology company’s stock valued at $2,238,000 after buying an additional 411 shares during the period. First Allied Advisory Services Inc. boosted its stake in Stryker by 4.6% during the second quarter. First Allied Advisory Services Inc. now owns 17,939 shares of the medical technology company’s stock valued at $3,688,000 after buying an additional 791 shares during the period. Commerce Bank boosted its stake in Stryker by 2.4% during the second quarter. Commerce Bank now owns 39,890 shares of the medical technology company’s stock valued at $8,201,000 after buying an additional 921 shares during the period. AGF Investments LLC bought a new stake in Stryker during the second quarter valued at $1,366,000. Finally, Clarus Wealth Advisors boosted its stake in Stryker by 19.3% during the second quarter. Clarus Wealth Advisors now owns 2,111 shares of the medical technology company’s stock valued at $434,000 after buying an additional 342 shares during the period. 73.13% of the stock is owned by institutional investors.
In related news, Director Srikant M. Datar sold 350 shares of the business’s stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $215.00, for a total transaction of $75,250.00. Following the transaction, the director now owns 6,844 shares in the company, valued at approximately $1,471,460. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP M Kathryn Fink sold 28,690 shares of the business’s stock in a transaction dated Thursday, September 19th. The shares were sold at an average price of $220.97, for a total value of $6,339,629.30. The disclosure for this sale can be found here. In the last quarter, insiders sold 67,524 shares of company stock worth $14,731,927. Company insiders own 7.20% of the company’s stock.
SYK has been the subject of several research analyst reports. Credit Suisse Group lifted their price objective on Stryker from $232.00 to $237.00 and gave the company an “outperform” rating in a research note on Friday, July 26th. Raymond James set a $240.00 price target on Stryker and gave the company a “buy” rating in a research report on Friday, July 26th. Stifel Nicolaus raised their price target on Stryker from $230.00 to $245.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Barclays downgraded Stryker from an “overweight” rating to an “equal weight” rating and lowered their price target for the company from $226.00 to $207.00 in a research report on Tuesday, November 5th. Finally, ValuEngine downgraded Stryker from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Six research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $220.17.
SYK opened at $198.42 on Tuesday. The company has a market cap of $74.74 billion, a P/E ratio of 27.14, a P/E/G ratio of 2.45 and a beta of 0.80. The business’s 50-day moving average price is $212.29 and its 200-day moving average price is $205.81. The company has a current ratio of 2.18, a quick ratio of 1.35 and a debt-to-equity ratio of 0.64. Stryker Co. has a 12 month low of $144.75 and a 12 month high of $223.45.
Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $1.91 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.90 by $0.01. The firm had revenue of $3.59 billion for the quarter, compared to the consensus estimate of $3.58 billion. Stryker had a return on equity of 25.33% and a net margin of 23.55%. The company’s quarterly revenue was up 10.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.69 earnings per share. Equities research analysts forecast that Stryker Co. will post 8.23 earnings per share for the current fiscal year.
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.